CompletedInterventionalPhase 3Updated Aug 24, 2018
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care | NCT00303407 | Trialant
TerminatedObservationalUpdated Mar 16, 2006
Prophylaxis of Venous Thrombo-Embolism in Cancer Patients Under Palliative Care
ClinicalTrials.gov ID
NCT00303407
Lead Sponsor
University Hospital, GenevaOTHER
Overall Status
Terminated
Study Type
Observational
Last Update Posted
Mar 16, 2006Estimated
Start Date
Jan 2001
Completion Date
Jul 2002
Brief Summary
To determine the efficacy and to measure the complications of prophylactic anticoagulation using low-molecular weight heparin in adult cancer patients under palliative care
Cancer
Venous Thromboembolism
nadroparin
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Cancer patients in palliative care
Patients fully informed about their condition
Signed informed consent
No exclusion criteria
Exclusion Criteria:
Absence of advanced cancer
Cancer previously cured
Venous thromboembolism diagnosed within 6 months prior to inclusion
Absence of discerning capacity
Active anti-thrombotic treatment with heparins or coumarines
Thrombocytopenia <50G/l
PTT >45sec
TP<35%
Active bleeding
Renal failure <20ml/min
Past history of heparin-induced thrombocytopenia
Observational Model
Defined Population
Time Perspective
Prospective
No central contacts
There are no central contacts for this study.
Center of Continuous Care, chemin de la Savonnière
Collonge-Bellerive (Geneva), Canton of Geneva 1245, Switzerland